# An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)

> **NCT00124098** · PHASE3 · COMPLETED · sponsor: **Amgen**

## Conditions studied

- Kidney Disease

## Interventions

- **DRUG:** Aranesp® (darbepoetin alfa)

## Key facts

- **NCT ID:** NCT00124098
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124098, "An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00124098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*